Boston Scientific Unveils AI-Enabled AVVIGO+ Multi-Modality Guidance System In India

Boston Scientific Corporation (NYSE: BSX) has introduced its latest innovation in cardiovascular care, the AVVIGO+ Multi-Modality Guidance System, to the Indian market. The new intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system is designed to enhance the precision and efficiency of percutaneous coronary interventions (PCI), offering physicians advanced vessel imaging and AI-powered lesion assessment.

The AVVIGO+ system leverages artificial intelligence (AI) to automate key procedural steps, significantly reducing procedure times and improving vessel measurement accuracy through its Automated Lesion Assessment feature. This cutting-edge tool also provides a detailed physiology graph to guide the treatment of coronary artery disease.

Madan R. Krishnan, vice president and managing director for the India Subcontinent at Boston Scientific, emphasised the importance of this technology for coronary interventions, stating, "The AVVIGO+ system brings fast, intuitive, and precise vessel and lesion assessment, optimising PCI procedures and improving outcomes for patients with coronary artery disease."

The system’s FFR technology allows physicians to assess coronary artery blockages with pressure sensors that measure blood flow, enabling informed treatment decisions. IVUS, meanwhile, offers high-resolution images from within the heart, helping doctors visualise coronary structures with unprecedented clarity.

Following its approval by the Central Drugs Standard Control Organisation (CDSCO) in July 2024, the AVVIGO+ system is now set to transform coronary interventions across India.